Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01661166 · ClinicalTrials.gov registry record · Phase 4
A Study of Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Lap. Prostatectomy
A Phase 4 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- Phase 4
- Development phase
- 3
- Enrollment target
NCT01661166: Completed Phase 4 study, sponsored by Abramson Cancer Center at Penn Medicine.
NCT01661166 is a Phase 4 study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 3 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01661166, a Phase 4 study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 3 participants
- Enrollment target
Study Summary
The investigators will assess the incidence of Overactive Bladder/Detrusor Overactivity (OAB/DO) post-operatively in patients post robotic assisted radical prostatectomy (RARP) and to investigate whether fesoterodine will alter the incidence of OAB/DO in these patients. Additionally, the correlation between OAB symptoms and urodynamic DO will be analyzed.
Interventions
- DRUG Placebo oral tablet
- DRUG Fesoterodine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2012-01 |
| Est. Completion | 2013-04-15 |
| Phase | Phase 4 |
What the finished NCT01661166 record still lists
NCT01661166 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo oral tablet is the first listed.
NCT01661166 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01661166 about?
NCT01661166 is a clinical study titled "A Study of Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Lap. Prostatectomy". The investigators will assess the incidence of Overactive Bladder/Detrusor Overactivity (OAB/DO) post-operatively in patients post robotic assisted radical prostatectomy (RARP) and to investigate whether fesoterodine will alter the incidence of OAB/DO in these patients. Additionally, the correlation...
What is the current status of trial NCT01661166?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 3 participants. The study started on 2012-01. Estimated completion is 2013-04-15.
What interventions are being tested in trial NCT01661166?
The interventions under investigation include: Placebo oral tablet (DRUG), Fesoterodine (DRUG).
Who is sponsoring clinical trial NCT01661166?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01661166's enrollment target sits among peer trials
3 1995th of 2000 higher than 3 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia